By Linda Martinez
Kodiak Sciences Inc. (NYSE:KOD) Director Robert Profusek acquired 10,000 shares of Kodiak Sciences stock in a transaction that occurred on Tuesday, October 9th. The shares were bought at an average price of $10.00 per share, with a total value of $100,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
NYSE:KOD opened at $9.90 on Friday. Kodiak Sciences Inc. has a 12-month low of $9.25 and a 12-month high of $11.10.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Read More: How is a Moving Average Calculated?
Receive News & Ratings for Kodiak Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kodiak Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.